Relapsed/Refractory Myeloma- Cytogenetics

“Patients with certain kinds of relapsed/refractory multiple myeloma can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab)…

If your multiple myeloma has been diagnosed as “relapsed and refractory” it means that you have probably undergone many different conventional MM therapies and have relapsed. “Relapsed/Refractory Multiple Myeloma” is difficult to treat. You may be open to different types of options. Consider cytogenetic testing.

The good news is that the trial discussed below offers hope. The bad news is that there is a lot that you just don’t know. You don’t really know the short, long-term and late stage side effects than can occur. You don’t know what sort of remission you can achieve. But as a MMer you probably have throught about all this before.

While you consider your conventional options you should also consider evidence-based non-conventional therapies as well. I am a long-term MM surivor and MM Cancer Coach. I have lived in complete remission from my MM since 1999 through a series of evidence-based non-conventional therapies.

Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.

To Learn More About Relapsed/Refractory Myeloma- click now

Thank you,

David Emerson

MM Survivor
MM Cancer Coach
Director PeopleBeatingCancer

Cytogenetics

“Cytogenetics is a branch of genetics that is concerned with how the chromosomes relate to cell behaviour, particularly to their behaviour during mitosis and meiosis.^[1] Techniques used include karyotyping, analysis of G-banded chromosomes, other cytogenetic banding techniques, as well as molecular cytogenetics such as fluorescent in situ hybridization (FISH) and comparative genomic hybridization (CGH).”

Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma

“Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab)…

To qualify for the study, patients’ tumor cells must express the NY-ESO or LAGE-1 proteins, or both. Expression is the process by which information from a gene is used to create a functional product like a protein…

Keytruda, which targets the PD-1 protein associated with some cancers, has shown promise against multiple myeloma in combination with other therapies. There is preclinical-trial evidence “to support the view that the combination of NY-ESO SPEAR T-cells and anti-PD-1 therapy may lead to meaningful anti-tumor activity,” Amado said…

NY-ESO-1 is a cancer antigen, or molecule that can trigger an immune response against cancer. Researchers have found high levels of its expression in multiple myelomas that carry a bleak prognosis…

It tested NYO-ESO spear in a previous Phase 1/2 single-arm clinical trial (NCT01352286) of 25 high-risk or relapsed myeloma patients with few remaining treatment options and low life expectancy. The treatment led to a complete response — or the disappearance of all signs of the cancer — in 70 percent of the patients within three months. Patients had high-dose chemotherapy and a stem cell transplant before receiving the modified T-cells…

Relapsed refractory multiple myeloma: a comprehensive overview.

“Most patients with relapsed/refractory multiple myeloma (RRMM) have been treated with drug combinations including a proteasome inhibitor (PI) and/or an immunomodulatory drug (IMiD). The goal of therapy for such patients is therefore to achieve disease control with acceptable toxicity and patient-defined decent quality of life.

Physicians face a difficult task not only deciding who to treat, but also when to treat and how to treat, utilizing knowledge of previously administered therapies, patient comorbidities, potential adverse events, and patient wishes to make such a critical decision.

New drugs and combination regimens are continuously underway thus broadening the options for therapy and giving way to a more individualized approach for patients with RRMM. The integration of novel agents into the treatment paradigm has shifted the perception of multiple myeloma (MM) from an incurable, fatal disease to a manageable, chronic one.

This comprehensive review addresses the results and challenges posed by many of the newer agents for the treatment of RRMM. It attempts to propose a universal strategy for optimal therapy decision-making thus answering three simple fundamental questions-when to treat, how to treat, and how long to treat for.

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Relapsed/Refractory Myeloma- Cytogenetics

“Patients with certain kinds of relapsed/refractory multiple myeloma can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab)…

Recommended Reading:

Cytogenetics

Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma

To qualify for the study, patients’ tumor cells must express the NY-ESO or LAGE-1 proteins, or both. Expression is the process by which information from a gene is used to create a functional product like a protein…

Relapsed refractory multiple myeloma: a comprehensive overview.

Leave a Comment:

4 comments

Popular posts

Multiple Myeloma Diet

Multiple Myeloma Survivor- A Different kind of Second Opinion-

C-B-D Enhances Velcade (BORT)

Are Endometrial Polyps Overtreated?